Publications by authors named "Simon Alvis"

Claim this Profile
A
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE).
Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, Ignacio Duran, Luc Dirix, Simon Alvis

J Immunother Cancer· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.
Rocio Garcia-Carbonero, Ramon Salazar, Ignacio Duran, Ignacio Osman-Garcia, Luis Paz-Ares, Simon Alvis

J Immunother Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus.
Sam Illingworth, Ying Di, Maxine Bauzon, Janet Lei, Margaret R Duffy, Simon Alvis

Mol Ther Oncolytics· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The interfacial lipid binding site on the potassium channel KcsA is specific for anionic phospholipids.
Phedra Marius, Simon J Alvis, J Malcolm East, Anthony G Lee

Biophys J· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interactions of anionic phospholipids and phosphatidylethanolamine with the potassium channel KcsA.
Simon J Alvis, Ian M Williamson, J Malcolm East, Anthony G Lee

Biophys J· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interactions of phospholipids with the potassium channel KcsA.
Ian M Williamson, Simon J Alvis, J Malcolm East, Anthony G Lee

Biophys J· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis